JP2023508011A - 不眠症を治療するためのレンボレキサントの使用 - Google Patents

不眠症を治療するためのレンボレキサントの使用 Download PDF

Info

Publication number
JP2023508011A
JP2023508011A JP2022537669A JP2022537669A JP2023508011A JP 2023508011 A JP2023508011 A JP 2023508011A JP 2022537669 A JP2022537669 A JP 2022537669A JP 2022537669 A JP2022537669 A JP 2022537669A JP 2023508011 A JP2023508011 A JP 2023508011A
Authority
JP
Japan
Prior art keywords
lemborexant
child
pharmaceutically acceptable
acceptable salt
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022537669A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023508011A5 (cg-RX-API-DMAC7.html
Inventor
アンドリュー サトリン,
マーガレット モリーン,
イシャニ ランドリー,
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eisai R&D Management Co Ltd
Original Assignee
Eisai R&D Management Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Management Co Ltd filed Critical Eisai R&D Management Co Ltd
Publication of JP2023508011A publication Critical patent/JP2023508011A/ja
Publication of JP2023508011A5 publication Critical patent/JP2023508011A5/ja
Priority to JP2025131238A priority Critical patent/JP2025160480A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Anesthesiology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2022537669A 2019-12-20 2020-12-18 不眠症を治療するためのレンボレキサントの使用 Pending JP2023508011A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025131238A JP2025160480A (ja) 2019-12-20 2025-08-06 不眠症を治療するためのレンボレキサントの使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962951638P 2019-12-20 2019-12-20
US62/951,638 2019-12-20
PCT/US2020/065891 WO2021127359A1 (en) 2019-12-20 2020-12-18 Use of lemborexant for treating insomnia

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025131238A Division JP2025160480A (ja) 2019-12-20 2025-08-06 不眠症を治療するためのレンボレキサントの使用

Publications (2)

Publication Number Publication Date
JP2023508011A true JP2023508011A (ja) 2023-02-28
JP2023508011A5 JP2023508011A5 (cg-RX-API-DMAC7.html) 2023-12-22

Family

ID=74191874

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022537669A Pending JP2023508011A (ja) 2019-12-20 2020-12-18 不眠症を治療するためのレンボレキサントの使用
JP2025131238A Pending JP2025160480A (ja) 2019-12-20 2025-08-06 不眠症を治療するためのレンボレキサントの使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025131238A Pending JP2025160480A (ja) 2019-12-20 2025-08-06 不眠症を治療するためのレンボレキサントの使用

Country Status (11)

Country Link
US (1) US20230051268A1 (cg-RX-API-DMAC7.html)
EP (1) EP4076463A1 (cg-RX-API-DMAC7.html)
JP (2) JP2023508011A (cg-RX-API-DMAC7.html)
KR (1) KR20220119065A (cg-RX-API-DMAC7.html)
CN (1) CN115003305A (cg-RX-API-DMAC7.html)
AU (1) AU2020408557A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022012246A2 (cg-RX-API-DMAC7.html)
CA (1) CA3165481A1 (cg-RX-API-DMAC7.html)
MX (1) MX2022007304A (cg-RX-API-DMAC7.html)
TW (1) TW202137986A (cg-RX-API-DMAC7.html)
WO (1) WO2021127359A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20260029363A (ko) * 2023-06-29 2026-03-04 얀센 파마슈티카 엔브이 셀토렉산트를 이용한 우울증 치료 방법

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018140093A1 (en) * 2017-01-27 2018-08-02 Obrien Christopher F Methods for the administration of certain vmat2 inhibitors

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0828751A4 (en) 1995-05-05 1999-01-20 Human Genome Sciences Inc HUMAN NEUROPEPTIDE RECEPTOR
US6309854B1 (en) 1996-12-17 2001-10-30 Smithkline Beecham Corporation Polynucleotides encoding ligands of the neuropeptide receptor HFGAN72
US5935814A (en) 1997-04-30 1999-08-10 Smithkline Beecham Corporation Polynucleotides encoding HFGAN72Y receptor
US6020157A (en) 1997-04-30 2000-02-01 Smithkline Beecham Corporation Polynucleotides encoding HFGAN72X receptor
US6166193A (en) 1997-07-25 2000-12-26 Board Of Regents, University Of Texas System Polynucleotides encoding MY1 receptor
RU2571414C2 (ru) 2010-09-22 2015-12-20 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Циклопропановые соединения
US9416109B2 (en) 2012-02-17 2016-08-16 Eisai R&D Management Co., Ltd. Methods and compounds useful in the synthesis of orexin-2 receptor antagonists
JP6659681B2 (ja) * 2014-10-23 2020-03-04 エーザイ・アール・アンド・ディー・マネジメント株式会社 不眠症を治療するための組成物および方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018140093A1 (en) * 2017-01-27 2018-08-02 Obrien Christopher F Methods for the administration of certain vmat2 inhibitors

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DAYAL, S., ET AL., CLINICAL PHARMACOLOGY & THERAPEUTICS, vol. Vol.105 Supplement S1, JPN6024052274, March 2019 (2019-03-01), pages 54 - 043, ISSN: 0005587168 *
JOURNAL OF CLINICAL SLEEP MEDICINE, vol. 13, no. 11, JPN6025017477, 2017, pages 1289 - 1299, ISSN: 0005587170 *
NEWS RELEASE 不眠障害治療薬「レンボレキサント」、日本において新薬承認申請書を提出, JPN6025017475, 2019, JP, ISSN: 0005587169 *
SLEEP, vol. Vol.41,Issue suppl_1, JPN6025017476, 2018, pages 157, ISSN: 0005587171 *

Also Published As

Publication number Publication date
BR112022012246A2 (pt) 2022-08-30
CA3165481A1 (en) 2021-06-24
MX2022007304A (es) 2022-08-22
US20230051268A1 (en) 2023-02-16
KR20220119065A (ko) 2022-08-26
EP4076463A1 (en) 2022-10-26
CN115003305A (zh) 2022-09-02
WO2021127359A1 (en) 2021-06-24
AU2020408557A1 (en) 2022-08-11
TW202137986A (zh) 2021-10-16
JP2025160480A (ja) 2025-10-22

Similar Documents

Publication Publication Date Title
KR101607081B1 (ko) 디피피-4 저해약과 다른 당뇨병 치료약과의 병용 또는 조합으로 이루어지는 의약
JP6251321B2 (ja) Dgat1阻害剤の使用
RU2703297C2 (ru) Композиции и способы для лечения бессонницы
CN110799181A (zh) 用于治疗睡眠呼吸暂停的方法和组合物
AU2014249534B2 (en) Use of levocetirizine and montelukast in the treatment of vasculitis
JP2024523945A (ja) 血糖値の管理方法ならびに糖尿病及び関連状態の治療
EA036103B1 (ru) Способы лечения субъектов с синдромом прадера-вилли или синдромом смита-магениса
CN119523985A (zh) 川芎嗪硝酮衍生物在预防和治疗糖尿病并发症疾病中的应用
JP2015537009A (ja) 痛風の治療におけるブシラミンの使用
CN111918655B (zh) 治疗患有慢性肾脏疾病的糖尿病受试者的方法
JP2025160480A (ja) 不眠症を治療するためのレンボレキサントの使用
TW200843741A (en) Pharmaceutical composition
TW201540300A (zh) 慢性腎臟病之進展抑制或改善用製劑
AU2026201519A1 (en) Lemborexant for treating sleep issues
KR102512518B1 (ko) 페마피브레이트를 함유하는 의약
CN104582701A (zh) 减轻体重的方法
KR20080028415A (ko) PPARγ 애고니스트를 함유하는 의약 조성물
CN101217960A (zh) 用于改善尿毒症的治疗药和处置方法
RU2844395C2 (ru) Лемборексант для лечения проблем со сном
KR20190074746A (ko) 시클로-히스프로를 유효성분으로 포함하는 당뇨병 예방 또는 치료용 약제학적 제제
WO2025194118A1 (en) Formulations and methods for alleviating sleep disorders
JP2019510777A (ja) Nsaid誘発性の心血管、脳血管又は腎血管の有害事象を治療するための方法
WO2026052068A1 (zh) 药物组合物的用途
HK40126039A (en) Methods and compositions for treating huntington's disease and its symptoms
Patil et al. Pharmaceutical Interactions in Drug Practices

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231214

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231214

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241224

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250220

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250507